Drug
Retogatein clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2011 | 1 |
| 2015 | 3 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 8
Diamyd Therapeutics AB (4) · Diamyd Medical AB (3) · Johnny Ludvigsson (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Lund University (2) · Norwegian University of Science and Technology (1) · Oslo University Hospital (1)
Often tested with
Tested in the same studies.
Glutamate decarboxylase 2 (7) · Vitamin D (4) · Etanercept (1) · Insulin (1) · Lansoprazole (1) · Sitagliptin (1)
Studies
Open first, then newest update. How each study uses retogatein is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 DiabetesTerminatedPhase 3Diamyd Medical ABNCT05018585Written as Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
- Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 DiabetesActive, not recruitingPhase 2Diamyd Medical ABNCT05683990Written as Diamyd
- Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of DiabetesCompletedPhase 2Norwegian University of Science and TechnologyNCT04262479Written as recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
- Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 DiabetesCompletedPhase 2Diamyd Medical ABNCT03345004Written as Diamyd
- EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 DiabetesCompletedPhase 2Johnny LudvigssonNCT02464033Written as GAD-Alum
- Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet AutoantibodiesTerminatedPhase 2Lund UniversityNCT02387164Written as Alum-GAD
- Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset SubjectsCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00529399Written as GAD-Alum
- GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)CompletedPhase 1Johnny LudvigssonNCT02352974Written as GAD-Alum
- Diabetes Prevention - Immune ToleranceCompletedPhase 2Lund UniversityNCT01122446Written as Diamyd
- Diabetes Virus Detection Project, Intervention With GAD-alumTerminatedPhase 2Oslo University HospitalNCT01129232Written as GAD-alum
- Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 DiabetesTerminatedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00837759Written as Diamyd
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENTTerminatedPhase 3Diamyd Therapeutics ABNCT00751842Written as rhGAD65
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)TerminatedPhase 3Diamyd Therapeutics ABNCT00723411Written as rhGAD65
- Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)CompletedPhase 2Diamyd Therapeutics ABNCT00456027Written as rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 DiabetesCompletedPhase 2Diamyd Therapeutics ABNCT00435981Written as rhGAD65 formulated in Alhydrogel® (Diamyd®)
Codes
What other systems call retogatein · ClinicalTrials.gg INT017291
- UNII (FDA) ME3BUS4RYTRETOGATEINOne source FDA
- NCI Thesaurus C216051RetogateinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ME3BUS4RYT | RETOGATEIN | One source FDA |
| NCI Thesaurus | C216051 | Retogatein | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.